Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today

Korro Bio, Inc. is at the center of one of biotech’s biggest shake‑ups of 2025. After releasing mixed early data from its lead RNA‑editing program, KRRO‑110, the company has announced deep layoffs, a strategic pivot in its pipeline and a 12‑month pause in its high‑profile collaboration with Novo Nordisk. The stock has responded with a brutal collapse.